Loncastuximab Tesirine

6 trials 2 recruiting LOncology

Filter these 6 trials by condition, phase, country and more.

Open in Search →

6 Registered trials

2 Recruiting

3 Completed trials

5 Sponsors

11 Countries

Phase III

Phase II/III

Phase II

Phase III: 1 Phase II/III: 1 Phase II: 4

Indications tested

Diffuse large B-cell lymphoma 3 High-grade B-cell lymphoma 2 Follicular lymphoma 2 Mantle cell lymphoma refractory 1 Mantle cell lymphoma recurrent 1

Sponsors using this IMP

Universitaet Muenster 2 ADC Therapeutics S.A. 1 Fondazione Italiana Linfomi Ets 1 Humanitas Mirasole S.p.A. 1 The University Of Birmingham 1

All trials

6 total

Combining Loncastuximab Tesirine and Epcoritamab in Relapsed/Refractory Diffuse Large B-cell Lymphoma (DLBCL) Not authorised

2023-509861-19-00 Phase II 1 country Universitaet Muenster
Glo-BNHL: A Global Study of Novel Agents in Paediatric and Adolescent Relapsed and Refractory B-cell Non-Hodgkin Lymphoma Recruiting

2024-510575-38-00 Phase II/III 6 countries The University Of Birmingham
Combining Loncastuximab Tesirine and Epcoritamab in Relapsed/Refractory Diffuse Large B-cell Lymphoma (DLBCL) Recruiting

2023-509861-19-01 Phase II 1 country Universitaet Muenster
Use of LOncastuximab Tesirine in patients with RElapsed/Refractory Diffuse Large B-Cell LYmphoma (DLBCL) or High Grade B-Cell Lymphoma (HGBC… Ended

2024-516929-31-00 Phase II 1 country Humanitas Mirasole S.p.A.
Consolidation with ADCT-402 (loncastuximab tesirine) after a short course of immunochemotherapy: a phase II study in BTKi-treated (or BTKi i… Ended

2024-511633-35-00 Phase II 1 country Fondazione Italiana Linfomi Ets
A Phase 3 Randomized Study of Loncastuximab Tesirine Combined with Rituximab Versus Immunochemotherapy in Patients with Relapsed or Refracto… Ended

2023-503916-33-00 Phase III 8 countries ADC Therapeutics S.A.

Showing 1–6 of 6 trials

← All drugs A–Z